Catalyst Wire Dossier Catalyst Wire Dossier

Rocatinlimab (AMG 451)

Rocatinlimab · Amgen
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Rocatinlimab (AMG 451), covering 2025-04-03 to 2026-06-26. Get the full timeline:

Most recent: Clinical Trial Results: A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) [Phase 3]

See pricing